Answers are grounded in this paper and cite their sources.
Osteosarcoma remains difficult to treat because surgery and chemotherapy can provide incomplete tumor control, cause systemic toxicity, and lack reliable local monitoring. In this study, a tumor-microenvironment-activated DOX@Cu2S@PDA@MnO2 nanoplatform was prepared by converting Cu2O nanocubes into hollow Cu2S, coating polydopamine, growing a MnO2 shell, and loading doxorubicin. The Cu2S/PDA structure enabled strong NIR absorption and drug loading, while MnO2 responded to acidic H2O2/GSH-rich conditions to promote O2 generation, ROS-related reactions, and enhanced T1 MRI contrast. The nanoplatform showed concentration-dependent photothermal conversion at 808 and 1024 nm, microenvironment-responsive DOX release, increased intracellular ROS, and stronger killing of 143B osteosarcoma cells under NIR irradiation than carrier or free-drug controls. In tumor-bearing mice, it enhanced MRI/photoacoustic signals, enabled local photothermal heating, markedly inhibited tumor growth, and increased H&E-defined tumor damage and TUNEL-positive apoptosis, especially with 1024 nm irradiation. Hemolysis, organ histology, hematology, and blood biochemistry indicated acceptable short-term safety after repeated intratumoral administration. These results support this Cu2S/PDA/MnO2-based platform for imaging-guided localized osteosarcoma therapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: